Latest research on Aripiprazole

Aripiprazole is an atypical antipsychotic medication used for the treatment of schizophrenia. It has also recently received FDA approval for the treatment of acute manic and mixed episodes associated with bipolar disorder. Aripiprazole appears to mediate its antipsychotic effects primarily by partial agonism at the D2 receptor. In addition to partial agonist activity at the D2 receptor, aripiprazole is also a partial agonist at the 5-HT1A receptor, and like the other atypical antipsychotics, aripiprazole displays an antagonist profile at the 5-HT2A receptor. Aripiprazole has moderate affinity for histamine and alpha adrenergic receptors, and no appreciable affinity for cholinergic muscarinic receptors.

Aripiprazole dosage

Seventy-five patients were taking atypical antipsychotics (Risperidone, Paliperidone, Clozapine, Aripiprazole, Ziprasidone, and/or Quetiapine) at a median Chlorpromazine equivalent dose of 349.20 (277.64) mg/day. [source, 2016]
We failed to find an association between individual AP drugs and QTc interval, but we observed that people on Aripiprazole were significantly less likely to show QTc prolongation, which persisted after controlling for AP dose and polypharmacy (Table 2). [source, 2016]
Dose ranges were 5–30mg/day Aripiprazole, 2–6mg/day Risperidone, 5–20mg/day Olanzapine, 40–160mg/day Ziprasidone, and 100–600mg/day Quetiapine. [source, 2015]
However, the patient and his family refused to take more than 5-mg Aripiprazole because of a concern of adverse events by dose escalation. [source, 2015]
By this time, he was taking daily doses of Aripiprazole (15 mg), sodium Valproate (800 mg), and Propranolol (30 mg). [source, 2015]
The daily dose of Aripiprazole was tapered and discontinued over 11 weeks after the appearance of torticollis. [source, 2015]
Nevertheless, one large double-blind, placebo-controlled trial of adjunctive low-dose Aripiprazole (2 mg/day) in MDD patients with inadequate response to prior antidepressant therapy (n=225) reported good tolerability, but only marginal efficacy over placebo [54]. [source, 2015]
After screening 5 259 citations (Figure 1), 17 articles were included in this review (Shelton et al., 2001, 2005; Corya et al., 2006; Khullar et al., 2006; Mattingly et al., 2006; Berman et al., 2007, 2009; Mahmoud et al., 2007; McIntyre et al., 2007; Thase et al., 2007; Marcus et al., 2008; Reeves et al., 2008; Bauer et al., 2009; Keitner et al., 2009; El-Khalili et al., 2010; Fava et al., 2012; Kamijima et al., 2013) comprised of 18 RCTs with a total of 4 422 patients treated with seven different types (and dosages) of atypical antipsychotic agents: standard-dose Aripiprazole (n = 746 patients), low-dose Aripiprazole (n = 253 patients), standard-dose olanzapine/fluoxetine (OFC, n = 599 patients), low-dose OFC (n = 59 patients), Quetiapine (mean 250–350mg daily, n = 345 patients), Quetiapine (mean 150–250mg daily, n = 344 patients), and standard-dose Risperidone (n = 217 patients). [source, 2015]
Compared with placebo, all standard-dose agents were significantly more effective (SMD ranged from -0.27 to -0.43), while low-dose OFC and low-dose Aripiprazole were not. [source, 2015]
In terms of the QoL/functioning outcome, only standard-dose Risperidone and standard-dose Aripiprazole were significantly more beneficial than placebo (SMD = -0.38, 95% CrI -0.65 to -0.12, and SMD = -0.26, 95% CrI -0.40 to -0.11, respectively). [source, 2015]